/TARO

TARO Stock - Taro Pharmaceutical Industries Ltd.

Q: What is the analyst price target for TARO?

Analyst price target information is not currently available for TARO.

Q: What is TARO's market cap?

Market capitalization information is not currently available for TARO.

Healthcare|Drug Manufacturers - Specialty & Generic|NYSE

$42.98+0.01%

+$0.01 (+0.01%) • Jun 21

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $47.27

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TARO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.56

52W High$45.76

52W Low$32.67

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$629.18M	$572.95M	$561.35M	$548.97M	$644.77M
Gross Profit	$304.98M	$268.32M	$293.12M	$296.66M	$399.73M
Gross Margin	48.5%	46.8%	52.2%	54.0%	62.0%
Operating Income	$21.51M	$17.71M	$184.37M	$704.44M	$246.53M
Net Income	$53.87M	$25.45M	$58.27M	$-400,740,000	$244.24M
Net Margin	8.6%	4.4%	10.4%	-73.0%	37.9%
EPS	$1.43	$0.68	$1.55	$-10.49	$6.35

Company Overview

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

$43

Average Target

↑ 0.1% Upside

Now

$43

Low

$43

Average

$43

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
January 18th 2024	H.C. Wainwright	Downgrade	Neutral	$43

Earnings History & Surprises

TARO

Beat Rate

37%

Last 19 quarters

Avg Surprise

-4.1%

EPS vs Estimate

Beats / Misses

7/12

Last 12 quarters

Latest EPS

$0.40

Q3 2024

EPS Surprise History

Q4 22

-108.3%

$-0.07vs$0.84

Q1 23

-78.2%

$0.19vs$0.87

Q2 23

-21.7%

$0.18vs$0.23

Q3 23

+29.0%

$0.40vs$0.31

Q4 23

+111.1%

$0.38vs$0.18

Q1 24

+80.0%

$0.54vs$0.30

Q2 24

+29.0%

$0.40vs$0.31

Q3 24

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Jul 24, 2024	—	$0.40	—	—
Q2 2024	May 20, 2024	$0.31	$0.40	+29.0%	✓ BEAT
Q1 2024	Jan 25, 2024	$0.30	$0.54	+80.0%	✓ BEAT
Q4 2023	Oct 26, 2023	$0.18	$0.38	+111.1%	✓ BEAT
Q3 2023	Jul 26, 2023	$0.31	$0.40	+29.0%	✓ BEAT
Q2 2023	May 23, 2023	$0.23	$0.18	-21.7%	✗ MISS
Q1 2023	Jan 24, 2023	$0.87	$0.19	-78.2%	✗ MISS
Q4 2022	Oct 27, 2022	$0.84	$-0.07	-108.3%	✗ MISS
Q3 2022	Jul 27, 2022	$0.85	$0.37	-56.5%	✗ MISS
Q2 2022	May 26, 2022	$0.88	$0.73	-17.0%	✗ MISS
Q1 2022	Jan 27, 2022	$0.91	$0.70	-23.1%	✗ MISS
Q4 2021	Oct 28, 2021	$1.02	$0.66	-35.3%	✗ MISS
Q3 2021	Jul 27, 2021	$0.84	$1.09	+29.8%	✓ BEAT
Q2 2021	May 19, 2021	$0.92	$0.81	-12.0%	✗ MISS
Q1 2021	Jan 27, 2021	$1.01	$0.86	-14.9%	✗ MISS
Q4 2020	Oct 28, 2020	$0.77	$1.18	+53.2%	✓ BEAT
Q3 2020	Jul 29, 2020	$1.16	$0.76	-34.5%	✗ MISS
Q2 2020	May 19, 2020	$1.53	$1.42	-7.2%	✗ MISS
Q1 2020	Feb 3, 2020	$1.54	$1.76	+14.3%	✓ BEAT
Q4 2019	Nov 4, 2019	$1.72	$1.46	-15.1%	✗ MISS

Frequently Asked Questions about TARO

What is TARO's current stock price?

Taro Pharmaceutical Industries Ltd. (TARO) is currently trading at $42.98 per share. The stock has moved +0.01% today.

What is the analyst price target for TARO?

No analyst price targets are currently available for this stock.

What sector is Taro Pharmaceutical Industries Ltd. in?

Taro Pharmaceutical Industries Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.

What is TARO's market cap?

Taro Pharmaceutical Industries Ltd. has a market capitalization of $1.62 billion, making it a small-cap company.

Does TARO pay dividends?

No, Taro Pharmaceutical Industries Ltd. does not currently pay a dividend to shareholders.